TAKARA BIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,086 JPY | -1.18% |
|
+5.95% | -13.26% |
| 05-10 | Takara Bio Inc. Proposes Dividend for the Fiscal Year Ending March 31, 2024, Effective June 24, 2024 | CI |
| 03-18 | Takara Bio Inc.(TSE:4974) dropped from FTSE All-World Index | CI |
ETFs positioned on Takara Bio Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.00% | 22 M€ | +3.79% | - | |
| 0.22% | 10 M€ | +7.50% | ||
| 0.06% | 57 M€ | +17.70% | ||
| 0.05% | 4 M€ | +17.30% | ||
| 0.04% | 2 M€ | -.--% | ||
| 0.03% | 70 M€ | +16.92% | ||
| 0.02% | 9,760 M€ | +17.51% | ||
| 0.02% | 4,929 M€ | +17.38% | ||
| 0.02% | 17 M€ | +11.76% | - | |
| 0.02% | 140,441 M€ | +17.30% | ||
| 0.02% | 20,360 M€ | +16.11% | - | |
| 0.02% | 63,295 M€ | +17.36% | - | |
| 0.01% | 746 M€ | -.--% | - | |
| 0.01% | 7 M€ | +6.58% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 32 M€ | +9.08% | - | |
| 0.00% | 34 M€ | +9.38% | - | |
| 0.00% | 391 M€ | +9.28% | - | |
| 0.00% | 39 M€ | +6.43% | - | |
| 0.00% | 306 M€ | +6.40% | - |
TAKARA BIO INC. is a Japan-based company principally engaged in bio-industry support business and gene medicine business. The Company operates in three business segments. Bioindustry Support segment provides reagents for research (genetic engineering reagents, cell engineering reagents, protein engineering reagents), scientific instruments, contract services and license fees for gene related patents to research institutes, such as universities and companies where biotechnology research and development are conducted. Gene Medicine segment provides gene therapy-related development and sale licensing fees and trial products as an application field of genetic engineering technology and cell engineering technology which is core technology cultivated in development of research reagents. Medical Food and Biotechnology segment provides health food and health food research and development services, license fees for health food related patents, as well as license fees for mushrooms.
Calendar
2024-08-05
- Q1 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,086
JPY
Average target price
1,567
JPY
Spread / Average Target
+44.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.26% | 852M | |
| +33.63% | 50.85B | |
| -0.09% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +11.18% | 26.11B | |
| -21.95% | 19.13B | |
| +8.61% | 13.05B | |
| +28.31% | 12.16B | |
| +24.73% | 12.08B |
- Stock Market
- Equities
- 4974 Stock
- Funds and ETFs Takara Bio Inc.
